MX2024006678A - Inhibidor de cdk4 para el tratamiento del cancer. - Google Patents
Inhibidor de cdk4 para el tratamiento del cancer.Info
- Publication number
- MX2024006678A MX2024006678A MX2024006678A MX2024006678A MX2024006678A MX 2024006678 A MX2024006678 A MX 2024006678A MX 2024006678 A MX2024006678 A MX 2024006678A MX 2024006678 A MX2024006678 A MX 2024006678A MX 2024006678 A MX2024006678 A MX 2024006678A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- cdk4 inhibitor
- administering
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163285320P | 2021-12-02 | 2021-12-02 | |
| US202263382346P | 2022-11-04 | 2022-11-04 | |
| US202263383969P | 2022-11-16 | 2022-11-16 | |
| PCT/IB2022/061525 WO2023100070A1 (en) | 2021-12-02 | 2022-11-29 | Cdk4 inhibitor for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006678A true MX2024006678A (es) | 2024-06-19 |
Family
ID=84440018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006678A MX2024006678A (es) | 2021-12-02 | 2022-11-29 | Inhibidor de cdk4 para el tratamiento del cancer. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250041298A1 (https=) |
| EP (1) | EP4440576A1 (https=) |
| JP (1) | JP2024542633A (https=) |
| KR (1) | KR20240112931A (https=) |
| AU (1) | AU2022400308B2 (https=) |
| CA (1) | CA3240993A1 (https=) |
| IL (1) | IL312650A (https=) |
| MX (1) | MX2024006678A (https=) |
| WO (1) | WO2023100070A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024201340A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof |
| CN120981721A (zh) | 2023-03-30 | 2025-11-18 | 辉瑞大药厂 | Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法 |
| EP4719405A1 (en) | 2023-06-02 | 2026-04-08 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105828822B (zh) * | 2013-08-14 | 2019-10-18 | 诺华股份有限公司 | 用于治疗癌症的组合疗法 |
| GEP20227433B (en) | 2018-04-26 | 2022-10-25 | Pfizer | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| WO2020157709A1 (en) * | 2019-02-01 | 2020-08-06 | Pfizer Inc. | Combination of a cdk inhibitor and a pim inhibitor |
| FI4181920T3 (fi) * | 2020-07-15 | 2025-11-20 | Pfizer | Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon |
| AU2021325426A1 (en) * | 2020-08-13 | 2023-03-09 | Astellas Pharma Inc. | Combination therapy |
| AU2021345531B2 (en) * | 2020-09-15 | 2024-02-29 | Pfizer Inc. | Solid forms of a CDK4 inhibitor |
| JP2024505680A (ja) * | 2021-02-05 | 2024-02-07 | ベラステム・インコーポレーテッド | 異常な細胞成長を処置するための併用療法 |
-
2022
- 2022-11-29 US US18/714,642 patent/US20250041298A1/en active Pending
- 2022-11-29 KR KR1020247021924A patent/KR20240112931A/ko active Pending
- 2022-11-29 CA CA3240993A patent/CA3240993A1/en active Pending
- 2022-11-29 MX MX2024006678A patent/MX2024006678A/es unknown
- 2022-11-29 AU AU2022400308A patent/AU2022400308B2/en active Active
- 2022-11-29 EP EP22818896.7A patent/EP4440576A1/en active Pending
- 2022-11-29 JP JP2024532158A patent/JP2024542633A/ja active Pending
- 2022-11-29 IL IL312650A patent/IL312650A/en unknown
- 2022-11-29 WO PCT/IB2022/061525 patent/WO2023100070A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20250041298A1 (en) | 2025-02-06 |
| CA3240993A1 (en) | 2023-06-08 |
| EP4440576A1 (en) | 2024-10-09 |
| JP2024542633A (ja) | 2024-11-15 |
| AU2022400308A1 (en) | 2024-05-16 |
| AU2022400308B2 (en) | 2026-02-12 |
| TW202329970A (zh) | 2023-08-01 |
| IL312650A (en) | 2024-07-01 |
| KR20240112931A (ko) | 2024-07-19 |
| WO2023100070A1 (en) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006678A (es) | Inhibidor de cdk4 para el tratamiento del cancer. | |
| EP4327882A3 (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
| MX2023002248A (es) | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. | |
| PH12021551833A1 (en) | Enpp1 inhibitors and methods of modulating immune response | |
| ZA202407596B (en) | Cancer treatments using mta-cooperative prmt5 inhibitors | |
| ZA202300875B (en) | Kat6 inhibitor methods and combinations for cancer treatment | |
| MX2024012131A (es) | Composicion farmaceutica, uso de la misma y metodo para tratar el cancer | |
| MX2023001717A (es) | Composiciones y metodos de agentes de la ruta del estres replicativo para el tratamiento del cancer. | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| MX2024004213A (es) | Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados. | |
| PH12022553501A1 (en) | Alk2 inhibitors for the treatment of anemia | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| MX2024014121A (es) | Metodos y composiciones para el tratamiento del exceso de glucocorticoides | |
| MX2024000674A (es) | Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| WO2020132560A3 (en) | Compositions and methods for cancer therapy | |
| MX2024004214A (es) | Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados. | |
| BR112022026247A2 (pt) | Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer | |
| MX2023006542A (es) | Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo. | |
| MX2022011725A (es) | Metodos para tratar una lesion pulmonar con inhibidores de cgrp. | |
| MX2025007373A (es) | Tratamientos del cancer con inhibidores de prmt5 cooperativos con mta | |
| MX2025007378A (es) | Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2 | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| MX2022008532A (es) | Inhibidores de hidrocarburo de arilo (ahr) y usos de estos. | |
| MX2025011364A (es) | Metodo de tratamiento de cancer de mama en estadio inicial con ribociclib en combinacion con un inhibidor de la aromatasa |